Seeking Alpha

needynicky's  Instablog

Send Message
View needynicky's Instablogs on:
  • OTI Begins Shipping New Order Of 10,000 NFC Readers To Major U.S. Unattended Point Of Sale System Integrator

    Total OTI Saturn Readers Sold Surpasses 600,000 Unit Milestone

    Rosh Pina, Israel – Jan. 14, 2014 – (CRWE Press Release) - On Track Innovations Ltd. (OTI) (NASDAQ: OTIV), a global leader in cashless payment solutions based on contactless transactions and near-field communication (NYSEMKT:NFC), has received an initial purchase order for 10,000 Saturn 6500™ readers from a leading U.S.-based systems integrator serving the unattended point of sale market segment.

    The order follows a successful pilot program completed in December. OTI has since begun to deliver volume shipments of Saturn 6500s to the integrator for distribution to its nationwide customer base.

    The Saturn 6500 is a secured NFC and contactless reader built specifically for the unattended machine market, providing quick and easy support for electronic payments. Such cashless payments can increase sales by 20% or more since it does not limit the purchase to the cash in a customer’s pocket.

    “This win represents another example of our NFC readers meeting the demanding needs of our global customers and partners,” said Ofer Tziperman, the company’s CEO. “A key determining factor in establishing this valuable new relationship was our ability to quickly customize our Saturn reader to meet the customer’s unique specifications under a strict timeline. This capability, coupled with our highly reliable and secure NFC technology, continues to provide significant competitive advantages where we are able to supplant existing competitive technology as well as create new opportunities for implementing our patented NFC-based systems.”

    The $50 billion unattended machine market presents a tremendous growth opportunity for OTI. There are more than 30 million food and drink vending machines worldwide, with a vast majority lacking cashless transaction capabilities. This is in addition to the increasing number of ticket machines, parking meters, supermarket self-checkouts, Laundromats, photo kiosks, internet access terminals, bike kiosks and other locations that involve unattended cashless transactions.

    “Our accelerating sales momentum and growing industry adoption as the ‘de facto standard’ for NFC technology reveals that the market is at a tipping point in the transition to cashless payments,” added Tziperman. “Given the strength of our IP and global presence, OTI is ideally positioned to capitalize on this multi-billion dollar revolution.”

    About the Saturn 6500 NFC Reader
    The Saturn 6500 NFC Reader offers convenient and flexible payment card transactions, by either magnetic stripe or by contact or contactless methods, and is fully certified by all leading card associations. The reader’s modular design is easily installed with various connection options, making the Saturn 6500 NFC Reader a perfect solution for pay-at-the-pump, drive-thru, vending machines, self-serve laundry and other unattended retail applications. The reader employs OTI’s patented ‘matched antenna’ technology that provides reliable and secure device communication.

    About OTI
    On Track Innovations Ltd. (OTI) is a leader in contactless and NFC applications based on its extensive patent and IP portfolio. OTI’s field-proven innovations have been deployed around the world to address NFC and other cashless payment solutions, petroleum payment and management, cashless parking fee collection systems and mass transit ticketing. OTI markets and supports its solutions through a global network of regional offices and alliances. For more information, visit

    Forward-Looking Statements
    This press release may contain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Because such statements deal with future events and are based on OTI’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of OTI could differ materially from those described in or implied by the statements in this press release. For example, forward-looking statements include statements regarding receipt of future consideration from the sale of OTI’s SmartID Division, OTI’s long term growth and profitability, further penetration of the NFC markets and execution of OTI’s growth plans. The forward-looking statements contained in this press release are subject to other risks and uncertainties, including those discussed in the “Risk Factors” section and elsewhere in OTI’s annual report on Form 20-F for the year ended December 31, 2012 and in subsequent filings with the Securities and Exchange Commission. Except as otherwise required by law, OTI disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise.

    Company Contact:
    Shlomi Eytan
    Chief Sales and Marketing Officer

    Investor Contact:
    Scott Liolios or Matt Glover
    Liolios Group, Inc.

    Source: On Track Innovations Ltd.

    Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

    Jan 15 6:17 PM | Link | Comment!
  • Epizyme And Celgene Advance EPZ-5676 DOT1L Inhibitor Clinical Program To Benefit Cancer Patients With Acute Leukemias, Achieving $25 Million Clinical Proof Of Concept Milestone

    – Epizyme Also Achieves $4 Million Development Candidate Milestone with GSK –

    – 2013 End-of-Year Cash Guidance Increased –

    – Five Clinical Proof of Concept Programs Planned in 2014 –

    Cambridge, Mass, Jan. 6, 2014 - (CRWE Press Release) - Epizyme, Inc. (Nasdaq:EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced the achievement of the proof of concept (POC) milestone in the EPZ-5676 DOT1L inhibitor clinical program, earning a $25 million payment under the company's collaboration with Celgene Corporation. The milestone was triggered by objective responses in patients with translocations of the MLL gene (MLL-r). These patients are currently enrolled in the fourth dose cohort in the dose escalation stage of the ongoing Phase 1 clinical study and are receiving uninterrupted treatment with EPZ-5676.

    Epizyme also announced today that a development candidate milestone has been achieved for one of the three histone methyltransferase (HMT) targets included in the company's collaboration with GlaxoSmithKline (NYSE:GSK), earning a $4 million payment.

    "2013 was a year of important accomplishments for Epizyme," said Robert Gould, Ph.D., chief executive officer, Epizyme. "We have achieved the proof of concept milestone for EPZ-5676, our first-in-class DOT1L inhibitor, in our Celgene collaboration, initiated an ongoing Phase 1 study of EPZ-6438, our first-in-class EZH2 inhibitor, in our Eisai collaboration, achieved a Development Candidate milestone in our GSK collaboration, and continue to advance our pipeline of personalized therapeutics for patients with genetically defined cancers."

    "We are very pleased with EPZ-5676's emerging clinical profile and progress as a potential personalized therapeutic for patients with genetically defined acute leukemias," said Dr. Gould. "We look forward to presenting the data from our ongoing Phase 1 study of EPZ-5676, including the dose escalation stage that has completed enrollment and the adult MLL-r expansion stage that is now enrolling patients, at a medical conference in 2014."

    Additionally, the European Medicines Agency's Committee for Orphan Medicinal Products recommended orphan drug designation for EPZ-5676 to the European Commission in December 2013. EPZ-5676 was granted orphan drug designation by the U.S. Food and Drug Administration in May 2013.

    Including the Celgene POC milestone and the GSK development candidate milestone, Epizyme estimates a 2013 end-of-year cash and account receivables position of approximately $145 million versus previous guidance of an end-of-year cash position of more than $115 million.

    Epizyme plans to have as many as five clinical proof of concept programs ongoing in 2014. For EPZ-5676, Epizyme's first-in-class DOT1L inhibitor, these include the ongoing adult MLL-r expansion stage, MLL-r in pediatric patients, and adult MLL-PTD patients. For EPZ-6438, Epizyme's first-in-class EZH2 inhibitor, these include adult non-Hodgkin lymphoma patients and also pediatric and young adult patients with synovial sarcomas, pending completion of the ongoing Phase 1 study.

    About EPZ-5676 and Epizyme's Collaboration with Celgene
    Epizyme is developing EPZ-5676, a small molecule inhibitor of DOT1L created with Epizyme's proprietary product platform, for the treatment of patients with acute leukemia in which the MLL gene is rearranged due to a chromosomal translocation (MLL-r) or a partial tandem duplication (MLL-PTD). Due to these rearrangements, DOT1L is misregulated, resulting in the increased expression of genes causing leukemia.

    Epizyme believes that EPZ-5676 was the first HMTi to enter human clinical development. Epizyme is currently conducting a two-stage Phase 1 study. The dose escalation stage has completed enrollment, and the adult MLL-r expansion stage is now enrolling patients. Additional information about this ongoing Phase 1 study can be found here:

    Epizyme retains all U.S. rights to EPZ-5676 and has granted Celgene an exclusive license to EPZ-5676 outside of the United States. Epizyme is working with Abbott to develop a companion diagnostic to identify MLL-r patients. Additional information about Epizyme's partnerships is available here:

    About Epizyme's Collaboration with GSK
    In January 2011, Epizyme entered into a collaboration and license agreement with GSK to discover, develop and commercialize novel small molecule HMT inhibitors directed to three targets from Epizyme's product platform. Additional information about the GSK collaboration is available here:

    About EPZ-6438 and Epizyme's Collaboration with Eisai
    Epizyme is developing EPZ-6438, a small molecule inhibitor of EZH2 created with our proprietary product platform, for the treatment of non-Hodgkin lymphoma patients who have an oncogenic (cancer-causing) point mutation in EZH2. In many human cancers, misregulated EZH2 enzyme activity results in misregulation of genes that control cell proliferation—without these control mechanisms, cancer cells are free to grow rapidly.

    In June 2013, Epizyme initiated a Phase 1/2 clinical trial of EPZ-6438 in patients with advanced solid tumors or with relapsed or refractory B-cell lymphoma. This program is currently in the dose escalation phase. The company believes EPZ-6438 is the second HMTi to enter human clinical development, following Epizyme's DOT1L inhibitor, EPZ-5676.

    Additional information about this program, including clinical trial information, may be found here:

    Epizyme granted Eisai a worldwide license to EPZ-6438 (Eisai refers to this therapeutic candidate as E7438), subject to Epizyme's right to opt in for co-development, co-commercialization and profit share arrangement with Eisai in the United States. Epizyme is working with Roche and Eisai to develop a companion diagnostic to identify patients with EZH2 point mutations. Additional information about these partnerships may be found here:

    About Epizyme, Inc.
    Epizyme, Inc. is a clinical stage biopharmaceutical company creating personalized therapeutics for patients with genetically defined cancers. Epizyme has built a proprietary product platform that the company uses to create small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases, or HMTs. HMTs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression. Genetic alterations can result in changes to the activity of HMTs, making them oncogenic (cancer-causing). By focusing on the genetic drivers of cancers, Epizyme's targeted science seeks to match the right medicines with the right patients for a personalized approach to cancer treatment.

    For more information, visit and connect with us on Twitter at @EpizymeRx.

    Cautionary Note on Forward-Looking Statements
    Any statements in this press release about future expectations, plans and prospects for the Company, including statements about the Company's strategy, future operations, clinical development of the Company's therapeutic candidates, expectations regarding the Company's cash balance and future expectations and plans and prospects for the Company and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation of future clinical trials, expectations of expanding ongoing clinical trials, availability and timing of data from ongoing clinical trials, whether interim results from a clinical trial will be predictive of the final results of the trial or results of early clinical trials will be indicative of the results of future trials, expectations for regulatory approvals, development progress of the Company's companion diagnostics, availability of funding sufficient for the Company's foreseeable and unforeseeable operating expenses and capital expenditure requirements, other matters that could affect the availability or commercial potential of the Company's therapeutic candidates or companion diagnostics and other factors discussed in the "Risk Factors" section of the Company's 10-Q filed with the Securities and Exchange Commission on October 23, 2013. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.


    Jeff Boyle
    Epizyme, Inc.

    Luke Dickinson
    202.955.6222 ext. 2503

    Stephanie Ascher
    Stern Investor Relations

    Source: Epizyme, Inc.

    Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

    Jan 08 12:11 AM | Link | Comment!
  • Crown Equity Holdings (CRWE) Targets Multi-Billion Dollar Social Networking Service Market

    Web-based social networking services make it possible to connect people who share interests and activities across political, economic, and geographic borders. Social networks are providing a different way for individuals to communicate digitally. These communities of hypertexts allow for the sharing of information and ideas, an old concept placed in a digital environment.

    Crown Equity Holdings Inc. (OTCPK:CRWE) is looking to deliver value for its stockholders in both the near and long term, and to improve the potential future growth for the company, is targeting the multi-billion dollar social networking service market.

    CRWE is currently developing a social networking service and phone app, CRWE Network (, that is designed to target all the communities in every state of the United States, with its geographic focus starting in Southern California and Las Vegas Nevada.


    You can visit CRWE Network at:

    Encinitas, CA -

    San Diego, CA -

    Costa Mesa, CA -

    Del Mar, CA -

    La Jolla, CA -

    Dana Point, CA -

    Huntington Beach, CA -

    Laguna Beach, CA -

    Las Vegas, NV -

    Long Beach, CA -

    Newport Beach, CA -

    Palos Verdes, CA -

    Redondo Beach, CA -

    San Clemente, CA -

    San Pedro, CA -

    CRWE‘s business plan is based on selling advertising to local businesses. Its goal is to facilitate exchanges of goods and services in a manner similar to Craigslist, a classified advertisements website with sections devoted to jobs, housing, personals, for sale, items wanted, services, community, gigs, résumés, and discussion forums.

    The business model merges traditional national ad campaigns with the flourishing hyper local business directory model. Along with national and international news, each site will have local news pertinent to its own home town community. The sales teams will be able to market to the blue chip big brands and local small businesses.

    CRWE offers advertising branding and marketing services as a worldwide online multi-media publisher.

    More about Crown Equity Holdings Inc. (OTCPK:CRWE) at


    Certain of the matters discussed in this communication about us and our subsidiaries future performance, including, without limitation, future revenues, earnings, strategies, prospects, consequences and all other statements that are not purely historical constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ materially from those anticipated. Such statements are based on management’s beliefs as well as assumptions made by and information currently available to management. When used herein, the words “anticipate,” “intend,” “estimate,” “believe,” “expect,” “plan,” “should,” “hypothetical,” “potential,” “forecast,” “project,” variations of such words and similar expressions are intended to identify forward-looking statements. Factors that may cause actual results to differ are often presented with the forward-looking statements themselves. Other factors that could cause actual results to differ materially from those contemplated in any forward-looking statements made by us herein are discussed in filings we make with the United States Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K and subsequent reports on Form 10-Q an d Form 8-K and available at Crown Equity Holdings' website

    Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

    Jan 05 4:25 PM | Link | Comment!
Full index of posts »
Latest Followers


More »
Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.